

Liuya Wei

List of Publications by Citations

Source: <https://exaly.com/author-pdf/754930/liuya-wei-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

18
papers

964
citations

7
h-index

19
g-index

19
ext. papers

1,312
ext. citations

9.5
avg, IF

4.19
L-index

#	Paper	IF	Citations
18	Silver nanoparticles: synthesis, properties, and therapeutic applications. <i>Drug Discovery Today</i> , 2015 , 20, 595-601	8.8	541
17	Modulating ROS to overcome multidrug resistance in cancer. <i>Drug Resistance Updates</i> , 2018 , 41, 1-25	23.2	238
16	Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance. <i>Drug Resistance Updates</i> , 2020 , 48, 100663	23.2	80
15	Microbiota in health and diseases.. <i>Signal Transduction and Targeted Therapy</i> , 2022 , 7, 135	21	28
14	The small molecule tyrosine kinase inhibitor NVP-BHG712 antagonizes ABCC10-mediated paclitaxel resistance: a preclinical and pharmacokinetic study. <i>Oncotarget</i> , 2015 , 6, 510-21	3.3	26
13	PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia. <i>Cancer Letters</i> , 2016 , 383, 220-229	9.9	20
12	Small molecular modulators of JMJD1C preferentially inhibit growth of leukemia cells. <i>International Journal of Cancer</i> , 2020 , 146, 400-412	7.5	16
11	Inhibition of the proliferation, migration, and invasion of human breast cancer cells by leucine aminopeptidase 3 inhibitors derived from natural marine products. <i>Anti-Cancer Drugs</i> , 2020 , 31, 60-66	2.4	5
10	Synthesis and characterization of dinuclear (Hedta)Ru(III) complexes with N-heterocyclic ligands: magnetic properties and DNA-binding studies. <i>Journal of Coordination Chemistry</i> , 2013 , 66, 3848-3856	1.6	4
9	LSD1 deletion decreases exosomal PD-L1 and restores T-cell response in gastric cancer.. <i>Molecular Cancer</i> , 2022 , 21, 75	42.1	2
8	The Histone Deacetylase Inhibitor I1 Induces Differentiation of Acute Leukemia Cells With MLL Gene Rearrangements Epigenetic Modification.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 876076	5.6	2
7	WB-PBPK approach in predicting zidovudine pharmacokinetics in preterm neonates. <i>Biopharmaceutics and Drug Disposition</i> , 2019 , 40, 341-349	1.7	1
6	A Stable Pep2-proapoptotic Peptide Inducing Apoptosis of Acute Myeloid Leukemia Cells by Down-Regulating EZH2. <i>Cellular and Molecular Bioengineering</i> , 2020 , 13, 165-177	3.9	1
5	Recent progress on targeting leukemia stem cells. <i>Drug Discovery Today</i> , 2021 , 26, 1904-1913	8.8	0
4	Discovery of 2-(4-Acrylamidophenyl)-Quinoline-4-Carboxylic Acid Derivatives as Potent SIRT3 Inhibitors.. <i>Frontiers in Chemistry</i> , 2022 , 10, 880067	5	0
3	The Histone Deacetylase Inhibitor I13 Induces Differentiation of M2, M3 and M5 Subtypes of Acute Myeloid Leukemia Cells and Leukemic Stem-Like Cells.. <i>Frontiers in Oncology</i> , 2022 , 12, 855570	5.3	0
2	Synthesis, oral bioavailability evaluation and antiplatelet aggregation activity of three derivatives of 3,4-dihydroxyacetophenone. <i>International Journal of Molecular Medicine</i> , 2020 , 45, 919-930	4.4	0

- 1 Research progress in overcoming ibrutinib drug resistance.. *Drugs of Today*, **2022**, 58, 85-94 2.5